Aclaris Therapeutics
ACRS
79 hedge funds and large institutions have $58.2M invested in Aclaris Therapeutics in 2019 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 24 increasing their positions, 26 reducing their positions, and 12 closing their positions.
11,100% more call options, than puts
Call options by funds: $112K | Put options by funds: $1K
85% more capital invested
Capital invested by funds: $31.4M → $58.2M (+$26.8M)
4.16% more ownership
Funds ownership: 70.29% → 74.45% (+4.2%)
8% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 26
2% less funds holding
Funds holding: 81 → 79 (-2)
17% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
MFN Partners
Boston,
Massachusetts
|
+$4.14M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$3.46M |
| 3 |
Renaissance Technologies
New York
|
+$1.35M |
| 4 |
Morgan Stanley
New York
|
+$1.31M |
| 5 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$473K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Man Group
London,
United Kingdom
|
-$4.04M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$2.28M |
| 3 |
D.E. Shaw & Co
New York
|
-$1.05M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$884K |
| 5 |
BlackRock
New York
|
-$650K |
ACRS Hedge Fund Activity: Q4 2019 in Review
79 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q4 2019, worth a combined $58.2M — up 85% from $31.4M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of ACRS and 10 opened new positions — a net loss of 2 holders — while 26 trimmed existing stakes and 24 added.
The largest buyer was MFN Partners, adding an estimated $4.14M. The largest seller was Man Group, cutting an estimated $4.04M.
- 79 institutional investors held Aclaris Therapeutics (ACRS) as of Q4 2019, down from 81 in Q3 2019.
- Funds reported $58.2M of Aclaris Therapeutics stock for Q4 2019, up 85% quarter-over-quarter.
- 10 funds opened new Aclaris Therapeutics positions in Q4 2019 and 12 closed out, a net change of -2 holders.
- The largest Aclaris Therapeutics buyer in Q4 2019 was MFN Partners, an estimated $4.14M added.
- The largest Aclaris Therapeutics seller in Q4 2019 was Man Group, an estimated $4.04M sold.
Based on aggregated 13F filings for Q4 2019.